REPL
Replimune Group, Inc. (NASDAQ)
Healthcare — Biotechnology
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Price History
Fundamentals
| Market Cap | $941.86M |
| P/E Ratio (TTM) | - |
| Forward P/E | -9.73 |
| EPS (TTM) | $-3.38 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -107.88% |
| Debt/Equity | 67.16 |
| Recommendation | Hold 2.9 |
| Analyst Target | $10.67 |
| Analysts | 6 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 78.6 |
| Beta | 0.87 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $13.24 |
| 52-Week Low | $1.50 |
| 50-Day Avg | $6.58 |
| 200-Day Avg | $7.27 |
| Avg Volume | $8.01M |
| Volume | $2.98M |
Performance Analysis
NEUTRALREPL presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:28 UTC
Back to Screener Export Report